Bass Expands Drug Patent Fight as Celgene, Shire Make Five

Updated on

Hedge fund manager Kyle Bass has expanded the number of drug companies whose patents he has targeted to five.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.